)
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
The US already contributes a significant share, around a quarter, of Cipla's total revenues
DTAB has accepted sub-panel recommendation on OTC drugs list
Sets price band of Rs 304-321 per share for IPO which opens on April 28
Hemant Sikka to head Mahindra Logistics, Veejay Nakra to head farm biz, R Veluswamy to head auto division
Kylaq success fuels confidence as carmaker eyes exports, higher India mkt share
Nuvama Institutional Equities said therapies like antidiabetic, anti-infective and respiratory had underperformed in the Indian pharma market
Most segments clock growth, commercial vehicle numbers decline: SIAM
Want govt to enforce anti-dumping duties, warn of mill closures and job losses
There are 21,757 permanent employees on company rolls as on March 31, 2024; cost optimisation to offset margin pressure due to declining Revlimid sales
According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 million in FY27
The overall luxury car market had grown by around 3 per cent in FY25
Despite looming tariffs, shipments to US grew 14%; EU and Africa next on the pharma export map
The Chetak was originally introduced in the 1970s, when it had a strong presence in the Indian scooter market for several decades
JLR posts flat volume growth for FY25
With its third acquisition in recent times, Metropolis' Ameera Shah said the firm will make another deal this financial year
Buyers are reassessing existing orders, with some seeking discounts. They are also exploring the best possible sources for imports, given the varied but steep reciprocal tariffs, exporters said
Policymakers should establish dedicated clinical research units within premier institutions like Aiims and NIPERs, regulatory authorities too would need support in developing their domain expertise
Analysts feel company will focus on profitable growth besides volume growth JLR likely to have 1-2 months' inventory in US which will now liquidate faster
Brokerages also felt that the pharma companies will aim to pass on the tariff hike to payors
Tariff worries, raw material costs still ail sector